Covid vaccine for children likely to be available by Sep: ICMR-NIV director

Coronavirus vaccine for children might be available for use in September or October this year, Dr Priya Abraham, the Director of Pune's ICMR-National Institute of Virology (NIV) informed

Covid vaccine for children likely to be available by Sep: ICMR-NIV director
ANI General News
2 min read Last Updated : Aug 19 2021 | 4:30 PM IST

Coronavirus vaccine for children might be available for use in September or October this year, Dr Priya Abraham, the Director of Pune's (Indian Council of Medical Research) ICMR-National Institute of Virology (NIV) informed.

In an interview with an OTT channel of the Department of Science and Technology, Abraham said, "Phase 2 and 3 trials of Covaxin are underway for children between 2-18 years. Hopefully, the results will be available soon, which will then be presented to the regulators. So, by September or just after it, we may have COVID-19 vaccines for children."

Further, she informed that apart from the Covaxin, Zyuds Cadila's vaccine trial for children is also underway. "Zydus Cadila's vaccine will be the first DNA vaccine available for use. Besides, there is Gennova Biopharmaceuticals Ltd's m-RNA, Biological -E vaccine, Serum Institute's Novovax and another interesting one is an intranasal vaccine by Bharat Biotech, which doesn't require a jab and can be delivered through nostrils," Abraham added.

Earlier in an interview with ANI, Dr Randeep Guleria, Director of AIIMS, on the COVID-19 vaccines for children had said, "Vaccines for children in India should come out now because trials are already underway for vaccines available in the country. Bharat Biotech's trials are in the final phase, and by September, we will have the data."

Talking about how effective the COVID-19 vaccine is on the Delta Plus variant, Dr Priya Abraham said, "Delta Plus variant is less likely to spread than the Delta variant, which is present in over 130 countries. In NIV, we have studied antibodies produced in vaccinated people and have checked them against this variant. The efficacy of antibodies against Delta reduces two-three folds. Yet, the vaccines are protective against the variants."

Saying that the WHO has put a momentary stop on the booster dose of the COVID-19 vaccine, she said, "Studies (on booster dose) have been going on overseas. At least seven different vaccines have been tried out for booster doses. The WHO has put a stop to it till more countries catch up with vaccination, but in the future, recommendations for booster dose will definitely come."

Recently, speaking about booster dose, Dr Gagandeep Kang, professor at Christain Medical College, Vellore, on Tuesday, had said that whether people will have more antibodies or will be better protected with the booster dose is still not known.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccinechildren

First Published: Aug 19 2021 | 4:30 PM IST

Next Story